Top-Rated StocksTop-Rated Denali Therapeutics Stock Price, News & Analysis (NASDAQ:DNLI) $18.37 -0.37 (-1.97%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$18.01▼$18.7250-Day Range$16.20▼$21.8352-Week Range$15.45▼$33.31Volume800,496 shsAverage Volume742,418 shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$50.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside172.2% Upside$50.00 Price TargetShort InterestBearish8.41% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.37Based on 5 Articles This WeekInsider TradingSelling Shares$105,641 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.01) to ($2.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector276th out of 954 stocksBiological Products, Except Diagnostic Industry32nd out of 129 stocks 3.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.00, Denali Therapeutics has a forecasted upside of 172.2% from its current price of $18.37.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.41% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 10.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 3.0 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Denali Therapeutics this week, compared to 2 articles on an average week.Search Interest15 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows9 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,641.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions78.04% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($1.01) to ($2.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -18.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; and DNL343 eIF2B Activator program for amyotrophic lateral sclerosis. The company's other programs comprise SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comHead-To-Head Review: Denali Therapeutics (NASDAQ:DNLI) and Innate Pharma (OTCMKTS:IPHYF)December 7, 2023 | finance.yahoo.comWhy Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?December 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 7, 2023 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Buy" by AnalystsDecember 5, 2023 | finance.yahoo.comAfter losing 39% in the past year, Denali Therapeutics Inc. (NASDAQ:DNLI) institutional owners must be relieved by the recent gainNovember 27, 2023 | finance.yahoo.comWall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?November 24, 2023 | benzinga.comDenali Therapeutics Stock (NASDAQ:DNLI), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comDenali Therapeutics Stock (NASDAQ:DNLI) Dividends: History, Yield and DatesDecember 8, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 19, 2023 | morningstar.comDenali Therapeutics Inc DNLINovember 9, 2023 | markets.businessinsider.comPromising Outlook for Denali Therapeutics: Leveraging the Superiority of TV Platform and OTV ApproachNovember 8, 2023 | finanznachrichten.deDenali Therapeutics Inc.: Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 7, 2023 | tmcnet.comDenali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 7, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn SituationNovember 6, 2023 | finance.yahoo.comWall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a BetNovember 1, 2023 | markets.businessinsider.comOptimistic Outlook for Denali Therapeutics: Emphasis on Promising Amyloid Clearance Kinetics and Potential Late-Stage DevelopmentOctober 5, 2023 | finance.yahoo.comShareholders in Denali Therapeutics (NASDAQ:DNLI) are in the red if they invested three years agoOctober 2, 2023 | msn.comDenali's New Summit: Changing Hunter Syndrome LandscapeSeptember 7, 2023 | finance.yahoo.comWhy Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?September 6, 2023 | markets.businessinsider.comDenali Therapeutics (DNLI) Receives a New Rating from B.Riley FinancialAugust 31, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)August 30, 2023 | finance.yahoo.comDenali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023August 29, 2023 | finance.yahoo.comInvaio achieves first registration for citrus greening solution featuring Trecise™ technologyAugust 11, 2023 | msn.comCantor Fitzgerald Reiterates Denali Therapeutics (DNLI) Overweight RecommendationAugust 10, 2023 | finance.yahoo.comPinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right NowAugust 9, 2023 | finanznachrichten.deDenali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Denali Therapeutics (DNLI)See More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees447Year Founded2015Price Target and Rating Average Stock Price Target$50.00 High Stock Price Target$105.00 Low Stock Price Target$28.00 Potential Upside/Downside+172.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,990,000.00 Net Margins-36.51% Pretax Margin-36.51% Return on Equity-11.54% Return on Assets-9.20% Debt Debt-to-Equity RatioN/A Current Ratio16.06 Quick Ratio16.06 Sales & Book Value Annual Sales$340.81 million Price / Sales7.45 Cash FlowN/A Price / Cash FlowN/A Book Value$7.68 per share Price / Book2.39Miscellaneous Outstanding Shares138,197,000Free Float127,279,000Market Cap$2.54 billion OptionableOptionable Beta1.11 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 47)Co-Founder, President, CEO & Director Comp: $1.04MDr. Alexander O. Schuth M.D. (Age 50)Co-Founder, CFO, COO & Secretary Comp: $737.2kDr. Marc Tessier-Lavigne Ph.D. (Age 63)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $58.23kDr. Carole Ho M.D. (Age 50)Chief Medical Officer & Head of Development Comp: $737.2kMr. Tyler M. Nielsen (Age 45)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsImmunocoreNASDAQ:IMCRImmunityBioNASDAQ:IBRXArcellxNASDAQ:ACLXBeam TherapeuticsNASDAQ:BEAMKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 30,282 shares on 12/6/2023Ownership: 0.100%Wellington Management Group LLPBought 250,784 shares on 12/1/2023Ownership: 5.274%Deutsche Bank AGSold 28,379 shares on 11/24/2023Ownership: 0.084%Tudor Investment Corp Et AlBought 42,020 shares on 11/16/2023Ownership: 0.030%Ironwood Investment Management LLCSold 623 shares on 11/16/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price target for 2024? 10 analysts have issued 1 year price targets for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $105.00. On average, they predict the company's share price to reach $50.00 in the next year. This suggests a possible upside of 172.2% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2023? Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have decreased by 33.9% and is now trading at $18.37. View the best growth stocks for 2023 here. Are investors shorting Denali Therapeutics? Denali Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 9,560,000 shares, a decrease of 10.9% from the October 31st total of 10,730,000 shares. Based on an average daily trading volume, of 854,200 shares, the days-to-cover ratio is currently 11.2 days. Approximately 8.4% of the company's shares are short sold. View Denali Therapeutics' Short Interest. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.09. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $11.16 million. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 11.54%. The firm's revenue for the quarter was down 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.84) earnings per share. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), BNY Mellon Innovators ETF (BKIV), Principal Healthcare Innovators ETF (BTEC), Harbor Corporate Culture Small Cap ETF (HAPS) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.62%), Wellington Management Group LLP (5.27%), Bank of New York Mellon Corp (1.43%), Federated Hermes Inc. (0.98%), Northern Trust Corp (0.81%) and FMR LLC (0.77%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DNLI) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.